Anika Therapeutics raises its 2026 adjusted EBITDA margin outlook and revenue growth projections after Q2 performance.
Anika Therapeutics revised its 2026 adjusted EBITDA margin forecast to 13%-17%, up from prior guidance, while raising its revenue growth outlook to 5%-10%. The company cited strong Q2 performance, including commercial channel revenue growth and gross margin expansion.
The updated projections follow a quarter where Anika reported its highest adjusted EBITDA since 2020. Management highlighted progress in building a more profitable business model, though specific prior guidance figures were not disclosed.
No immediate market reaction was detailed in the earnings call summary.